Mostrando 10 resultados de: 14
Filtros aplicados
Subtipo de publicación
Article(14)
Publisher
Canadian Journal of Cardiology(2)
New England Journal of Medicine(2)
The Lancet(2)
American Heart Journal(1)
Diabetes, Obesity and Metabolism(1)
Área temáticas
Enfermedades(13)
Farmacología y terapéutica(7)
Cirugía y especialidades médicas afines(1)
Fisiología humana(1)
Ginecología, obstetricia, pediatría, geriatría(1)
Basal insulin and cardiovascular and other outcomes in dysglycemia
ArticleAbstract: Background: The provision of sufficient basal insulin to normalize fasting plasma glucose levels mayPalabras claves:Autores:Abdallah A., Ahmad S., AHUAD GUERRERO R.A., Alebuena A., Alvarez N., Alzogaray M., Amuchastegui M., Andres M., Angos M., Avezum A.J., Baglivo H., Bahit M.C., Barbieri M., Bassi F., Bello F., Birkeland K.I., Bogaty P.M., Bono J., Bordeleau L., Bosch J.J., Budaj A.J., Bustamante Labarta M., Bustos B., Cardona E., Chacόn C., Chandra J., Chandra R., Chazova I.E., Commerford P.J., Corson M., Cukierman-Yaffee T., Dagenais G.R., Danilova L., Davies M., Díaz R., Dyal L., Fernando R., Fodor G.J., Gerstein H.C., Gilbert R., Gomis R., Halon D., Hâncu N., Hanefeld M., Harper W.L., Hildebrandt P., Johnston P., Joldersma L., Jung H., Kacerovsky-Bielesz G., Keltai M., Kim J.H., Krum H., Kultursay H., Lanas F.T., Lewis B.S., Lonn E.M., MacRae L., MacRae S., Maggioni A.P., Magloire P., Malik S., Mann J.F.E., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mead A., Mendoza I., Morillo C.A., Pan C., Pasha F., PATRICIO LOPEZ -JARAMILLO, Pavlova V., Pazmino-Canizares J., Pirags V., Pogue J., Pohl K., Probstfield J.L., Profozic V., Punthakee Z., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rydén L.E., Sakalas A., Silva J., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Tsang B., Tyrwhitt J., Vige R., Yakubovich N., Yale J.F., Yusuf S.Fuentes:scopusDesign and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
ArticleAbstract: The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucaPalabras claves:antidiabetic drug, Cardiovascular disease, Clinical trial, diabetes complications, GLP-1 receptor agonistAutores:Atisso C.M., Avezum A.J., Basile J.N., Cardona-Munoz E.G., Chung N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., DIaz R., Franek E., Gerstein H.C., Hâncu N., Hanefeld M., Holt S., Jansky P., Keltai M., Lakshmanan M., Lanas F., Leiter L.A., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:scopusEzetimibe added to statin therapy after acute coronary syndromes
ArticleAbstract: BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk ofPalabras claves:Autores:Armstrong P., Aylward P.E., Azize G., Ballantyne C., Bassand J., Beloscar J., Beltrano M., Berra F., Blazing M.A., Bluguermann J., Blumberg E., Bohula E.A., Bono J., Brady A.J.B., Braunwald E., Britto F., Califf R.M., Cannon C.P., Carlessi C., Carlevaro O., Carrageta M., CARTASEGNA L.U.I.S., Caruso O., Casalins M., Castoldi M., Centeno E., Cocco N., Colombo H., Corbalan R., Dalby A.J., Darius H., De Ferrari G.M., de Lemos J., De Lucca P., Dellatorre M., Dellborg M., Duris T., Duronto E., Egido J., Fanuele M., Farnier M., Fernandez H., Fernández R.O., Genest J., Giugliano R.P., Grande P., Guerrero R., Guneri S., Gurfinkel E., HOMINAL M.A., Im K.A., Isaza D., Jukema J.W., Keltai M., Kesaniemi A., Kleiman N.S., Lewis B.S., López-Sendón J.L., Lozada A.F., Mach F., MACIN S.M., Maffeo H., Mathur A., Maurer G., Mauro D., McCagg A., McGuire D., Milesi R., Mittal S., Musliner T.A., NANI S., Nicolau J.C., Ophuis T.O., Parkhomenko A.N., Pedersen T., Procopio G., Ramos H., Reddy K., Reges P., Reist C., Ricart J., Ruiz N., Ruzyllo W., Schmuck R., Seung K., Spinar J., Terns P., Tershakovec A.M., Theroux P., Tonkin A.M., Turri D., Van de Werf F., Viso M., Voitk J., White H.D., White J.A., Wiviott S.D., Yan Duarte, Zarandon R.Fuentes:scopusErectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial
ArticleAbstract: Background: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 rPalabras claves:Autores:Bajaj H.S., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Franek E., Gerstein H.C., Hanefeld M., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Shaw J.E., Sheu W.H.H., Xavier D.Fuentes:googlescopusDulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
ArticleAbstract: Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people wPalabras claves:Autores:Abella M., Alebuena A., Almagro S., Amoroso E., Anadon P., Andreu E., Aristimuño G., Arzadun M., Atisso C.M., Avezum A.J., Barbieri M., Barcudi R., BARTOLACCI I.P., Basile J.N., Bolobanich G., BORDONAVA A.P., Botros F.T., Bustamante Labarta M., Bustos B., CACCAVO A., Camino A., Cantero M., Cardona-Munoz E.G., Carignano M., CARTASEGNA L.U.I.S., Chung N., Cipullo M., Colhoun H.M., Commendatore V., Conget I., Conosciuto V., Costamagna O., Crespo C., Cuello J.L., Cuneo C.A., Cushman W.C., Cusimano S., Dagenais G.R., Dean S., DIaz R., Dituro C., Dominguez A., Dyal L., Farah M., Fernandez A., Fernandez F., Ferrari A., Flammia P., Franek E., Fuentealba J., Gallardo K.B., Garcia C., GARCIA DURAN R.O., GARRIDO M., Gavicola R., Gerbaudo C., Gerstein H.C., Gilli G., Giotto A.P., Godoy Bolzán P., Gomez Vilamajo O., Guerlloy F., Guridi C., Gutierrez Garrido N., Hall S., Hâncu N., Hanefeld M., HASBANI E., Hermida S., Holt S., HOMINAL M.A., HRABAR A., Ingaramo A., Izzicupo A., Jansky P., Keltai M., Krynski M., Lagrutta M., Lakshmanan M., Lanas F.T., Lanchiotti P., Langhe M., Leiter L.A., Leonard V., Llanos J., López-Santi R., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Washington Stalin García Cuenta, Wong G., Xavier D.Fuentes:googlescopusEffects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): A randomised controlled trial
ArticleAbstract: Background: Trials of β blockers in patients undergoing non-cardiac surgery have reported conflictinPalabras claves:Autores:Aggarwala R., Alonso-Coello P., Argibay-Poliquin E., Avezum A.J., Badner N., Baer C., Baidel Y., Baptista M., Barratt S., Beattie W.S., Bednarowski M., Beilby D., Bertozzi H.A., Berwanger O., Blacher C., Bodanese L.C., Boisvenu G., Bolsin S., Boulton A., Boyd D., Brunet D., Bryson G.L., Bugler S., Burlingham J., Caccavo R.A., Campeau J., Campos De Albuquerque D., Carlos Zevallos J., Chan M.T.V., Choi P., Chrolavicius S., Ciapponi A., Cope L., Devereaux P.J., Do Amara Baruzzi A.C., Douglas J., Esteves J.P., Faller J., Fatovich S., Ferrari A., Foëx P., França Neto O.R., Gannedahl P., Garcia Dieguez M., Giles J., Goldman L., Grant J., Greenspan L., Guiselli Gallina L.E., Guyatt G.H., Halliwell R., Hudson R.J., Islas Andrade S., Izukawa N.M., Jacka M.J., Kallas F.C., Keltai M., Kerr Saraiva J.F., Kerridge R.K., Leino K., Leslie K., Liu L., Love J., Málaga G., March S., Marin-Neto J.A., Mauricio Espinel, McCulloch T.J., Montori V.M., Myles P.S., Nicolosi L.N., Nigro Maia L., Paech M., Pais P., Penha Rosateli P.H., Peyton P., Phrommintikul A., Pogue J., Poole C., Poustie S., Priestly M., Rabello R., Raeder J., Reeves M., Salazar A., Schammass Ducatti T., Schricker T., Sear J., Sierra F., Tesolin P., Tristan M., Urŕutia G., Wallace S., Warriner B., Weitkamp B., Wolfers D., Xavier D., Xu S., Yang H., Yusuf S.Fuentes:scopusEffects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention: An analysis of the HOPE-3 trial
ArticleAbstract: Background-It is not clear whether the effects of lipid-lowering or antihypertensive medications arePalabras claves:Antihypertensive agent, statinAutores:Avezum A.J., Bogaty P.M., Bosch J.J., Dagenais G.R., Dehghan M., Held C., Jansky P., Jung H., Keltai M., Leiter L.A., Lonn E.M., PATRICIO LOPEZ -JARAMILLO, Toff W.D., Yusuf S.Fuentes:googlescopusNovel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
ArticleAbstract: Background: Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drPalabras claves:Autores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Dans A.M., DIaz R., Fodor G.J., Held C., Jansky P., Keltai K., Keltai M., Kim J.H., Kunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Pogue J., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusLowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
ArticleAbstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) ePalabras claves:Cardiovascular disease, Primary Prevention, statinsAutores:Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusSafety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
ArticleAbstract: Background & Aims: Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. TPalabras claves:bacteria, CVD, Reflux, ThrombosisAutores:Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopus